← Holders
Elmind Capital, LP
What Elmind Capital, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2052213 · Filed Nov 16, 2026
- Positions
- 30
- Reported value
- $403.8M
- Opened
- 0
- Closed
- 5
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Dec 31, 2025$338.9M34 positions
- Mar 31, 2026$352.2M34 positions
- Jun 30, 2026$398M35 positions
- Sep 30, 2026$403.8M30 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
CLDXCelldex Therapeutics, Inc. | 1.1M | +12.1% | $36M | 8.9% |
LEGNLegend Biotech Corp | 1.6M | +175.1% | $31.2M | 7.7% |
SNDXSyndax Pharmaceuticals Inc | 1.6M | −13.5% | $30.2M | 7.5% |
COGTCogent Biosciences, Inc. | 866.7K | −26.0% | $27.8M | 6.9% |
RLAYRelay Therapeutics, Inc. | 1.5M | ±0% | $26.4M | 6.5% |
AMLXAmylyx Pharmaceuticals, Inc. | 894.8K | +698.9% | $26M | 6.4% |
VRDNViridian Therapeutics, Inc. | 1.2M | +24.4% | $25.2M | 6.2% |
PCVXVaxcyte, Inc. | 372.3K | −17.7% | $21.2M | 5.2% |
URGNUroGen Pharma Ltd. | 491.1K | +309.3% | $20M | 4.9% |
TVTXTravere Therapeutics, Inc. | 322.6K | +10.3% | $19M | 4.7% |
CGEMCullinan Therapeutics, Inc. | 962.8K | +39.5% | $14.8M | 3.7% |
PHVSPharvaris N.V. | 455.8K | −13.3% | $14.5M | 3.6% |
VERAVera Therapeutics, Inc. | 436.5K | ±0% | $14.1M | 3.5% |
CTMXCytomX Therapeutics, Inc. | 4.6M | ±0% | $12.4M | 3.1% |
BEAMBeam Therapeutics Inc. | 476.3K | ±0% | $11.6M | 2.9% |
NRIXNurix Therapeutics, Inc. | 460K | ±0% | $10.9M | 2.7% |
SMMTSummit Therapeutics Inc. | 493.8K | ±0% | $8.4M | 2.1% |
UTHRUnited Therapeutics Corp | 15K | ±0% | $8.1M | 2% |
IMCRImmunocore Holdings plc | 256.1K | +215.7% | $7.8M | 1.9% |
KRYSKrystal Biotech, Inc. | 22K | ±0% | $7.3M | 1.8% |
ALMSAlumis Inc. | 749.6K | +476.6% | $5.5M | 1.4% |
BCRXBiocryst Pharmaceuticals Inc | 520K | ±0% | $4.3M | 1.1% |
STROSutro Biopharma, Inc. | 228.3K | +612.5% | $3.7M | 0.9% |
MBXMBX Biosciences, Inc. | 61K | −33.0% | $3.6M | 0.9% |
DBVTDBV Technologies S.A. | 265K | ±0% | $3.1M | 0.8% |
SUPNSupernus, Inc. | 70K | ±0% | $3M | 0.7% |
BMRNBioMarin Pharmaceutical Inc | 47K | ±0% | $2.8M | 0.7% |
SEPNSepterna, Inc. | 49.4K | ±0% | $1.9M | 0.5% |
ALECAlector, Inc. | 915.9K | +1.8% | $1.7M | 0.4% |
DSGNDesign Therapeutics, Inc. | 107.9K | ±0% | $1.4M | 0.3% |